David Jakeman Biography and Net Worth

Insider of Chimerix


Executive Director-Finance & Accounting, Chimerix, Inc.
Currently, David Jakeman occupies the position of Executive Director-Finance & Accounting at Chimerix, Inc.

Mr. Jakeman received an undergraduate degree and a graduate degree from The University of North Carolina at Charlotte.

What is David Jakeman's net worth?

The estimated net worth of David Jakeman is at least $142,644.32 as of February 14th, 2024. Mr. Jakeman owns 141,232 shares of Chimerix stock worth more than $142,644 as of March 28th. This net worth evaluation does not reflect any other assets that Mr. Jakeman may own. Learn More about David Jakeman's net worth.

How do I contact David Jakeman?

The corporate mailing address for Mr. Jakeman and other Chimerix executives is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. Chimerix can also be reached via phone at (919) 806-1074 and via email at [email protected]. Learn More on David Jakeman's contact information.

Has David Jakeman been buying or selling shares of Chimerix?

Over the course of the past ninety days, David Jakeman has sold $2,766.40 in Chimerix stock. Most recently, David Jakeman sold 2,660 shares of the business's stock in a transaction on Wednesday, February 14th. The shares were sold at an average price of $1.04, for a transaction totalling $2,766.40. Following the completion of the sale, the vice president now directly owns 141,232 shares of the company's stock, valued at $146,881.28. Learn More on David Jakeman's trading history.

Who are Chimerix's active insiders?

Chimerix's insider roster includes David Jakeman (Insider), Robert Meyer (Director), and Fred Middleton (Director). Learn More on Chimerix's active insiders.

Are insiders buying or selling shares of Chimerix?

In the last twelve months, Chimerix insiders bought shares 6 times. They purchased a total of 121,155 shares worth more than $135,181.60. In the last twelve months, insiders at the biopharmaceutical company sold shares 4 times. They sold a total of 9,954 shares worth more than $10,171.66. The most recent insider tranaction occured on February, 14th when CEO Michael T Andriole sold 1,744 shares worth more than $1,813.76. Insiders at Chimerix own 10.0% of the company. Learn More about insider trades at Chimerix.

Information on this page was last updated on 2/14/2024.

David Jakeman Insider Trading History at Chimerix

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/14/2024Sell2,660$1.04$2,766.40141,232View SEC Filing Icon  
9/28/2023Sell3,610$0.99$3,573.90133,142View SEC Filing Icon  
1/26/2023Sell3,230$1.76$5,684.80136,752View SEC Filing Icon  
9/29/2022Sell4,400$1.86$8,184.00127,532View SEC Filing Icon  
2/4/2022Sell3,300$5.56$18,348.00View SEC Filing Icon  
9/30/2021Sell4,590$6.19$28,412.10View SEC Filing Icon  
4/5/2021Sell1,284$9.68$12,429.12View SEC Filing Icon  
1/28/2021Sell3,211$8.61$27,646.7196,906View SEC Filing Icon  
10/2/2020Sell4,270$2.48$10,589.60
See Full Table

David Jakeman Buying and Selling Activity at Chimerix

This chart shows David Jakeman's buying and selling at Chimerix by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Chimerix Company Overview

Chimerix logo
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 2 clinical trial for treating tumors, which harbor the H3 K27M mutation in glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2 (COVID-19) infection. The company has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $1.07
Low: $1.01
High: $1.08

50 Day Range

MA: $1.06
Low: $0.91
High: $1.26

2 Week Range

Now: $1.07
Low: $0.88
High: $1.57

Volume

256,956 shs

Average Volume

422,851 shs

Market Capitalization

$95.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.16